IP Verse

Suppression Of Bone Cancer-Induced Allodynia

Patent No. EP3796929 (titled "Suppression Of Bone Cancer-Induced Allodynia") was filed by Ipsen Biopharm on May 21, 2019. The application was issued on Sep 18, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MERZ PHARMAJun 18, 2025WALLINGER RICKER SCHLOTTER TOSTMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3796929

IPSEN BIOPHARM
Application Number
EP19725358A
Filing Date
May 21, 2019
Status
Granted And Under Opposition
Aug 15, 2024
Publication Date
Sep 18, 2024
External Links
Slate, Register , Google Patents